Press Release

ZEISS VISUMAX 800 with SMILE pro software receives approval in China

Updated ZEISS femtosecond laser provides refractive surgeons in China with faster treatment, greater flexibility, and significant workflow enhancements.

26 February 2025

Jena, Germany / Shanghai, China | February 26, 2025 | Carl Zeiss Meditec AG

ZEISS Medical Technology announced today that the National Medical Products Administration (NMPA) in China has approved the VISUMAXĀ® 800 with SMILEĀ® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism. The latest generation of femtosecond lasers from ZEISS enters the China market at a time when more than 10 million eyes have been treated with ZEISS SMILE and SMILE pro worldwide, reflecting the technologyā€™s broad global momentum driven by strong adoption in Asia, Europe and the U.S.

"With the growing interest in laser vision correction in China, the market needs innovative technology that enhances surgical outcomes, safety and efficiency to benefit both surgeons and their patients. The availability of the ZEISS VISUMAX 800 with SMILE pro software further extends our commitment to ophthalmologists and helps to solidify the future of laser vision correction across China," says Maximilian Foerst, Head of ZEISS Greater China.

"ZEISS further sets itself apart in the China market with the availability of the VISUMAX 800 with SMILE pro software from ZEISS, providing the latest digital technology to meet the evolving needs of refractive surgeons worldwide," said Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "This next-generation femtosecond laser system creates data-driven insights to help surgeons better manage treatment paths for patients while supporting each surgeonā€™s unique practice requirements for greater workflow efficiency and performance."

VISUMAXĀ® 800 with SMILEĀ® pro software

The VISUMAXĀ® 800 with SMILEĀ® pro software from ZEISS enables faster treatment, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz.* Additionally, the shorter procedure time can reduce stress for surgeons and their patients. The ZEISS femtosecond laser also provides greater flexibility for the surgeon and patient, with a smaller footprint and compatibility with a variety of patient beds, adapting to the clinical environment to provide cutting-edge technology without compromise.

With the availability of the VISUMAXĀ® 800 with SMILEĀ® pro software from ZEISS in China, surgeons can utilize a number of workflow enhancements including: the CentraLignĀ® centration aid, a computer-controlled function for easy centration; the OcuLignĀ® cyclotorsion adjustment to help counter cyclotorsion that may occur; and VISULYZE user nomograms to help surgeons collect and analyze patient data, while also providing detailed nomograms and enabling more control during every surgery.

With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAXĀ® 800 with SMILEĀ® pro software from ZEISS offers substantial market opportunities for surgeons in China. For more information about the VISUMAXĀ® 800 with SMILEĀ® pro software from ZEISS, visit https://zeiss.com/visumax800

* Data on file, myopia with optical zone 6.5 mm.

Portrait of Sebastian Frericks
Investor Relations Contact Sebastian Frericks

Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG

Portrait of Frank Smith
Press contact Frank Smith

Head of Global Communications Ophthalmology
Carl Zeiss Meditec Inc.

Brief profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of ā‚¬2,066.1m in fiscal year 2023/24 (to 30 September).

The Groupā€™s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AGā€™s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the worldā€™s leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med

Press Photos

  • ZEISS VISUMAX 800 with SMILEĀ® pro software

    1 MB



Share this page